Keytruda (pembrolizumab) — Filing acceptance
H2 2026
FDA set Prescription Drug User Fee Act (PDUFA) dates in the second half of 2026 for these applications.Source filing
MRK biotech catalysts & pipeline
MERCK & CO INC · Data as of 2026-10-27
Upcoming catalysts
Keytruda (pembrolizumab) — Conference presentation
Oct 23–Oct 27
These late-breaking results will be presented for the first time during Presidential Symposium I at the European Society for Medical Oncology (ESMO) Congress 2026 (Presentation #LBA1), were selected for an official ESMO Press Briefing and have been accepted for publication in The New England Journal of Medicine .Source filing
Keytruda (pembrolizumab) — Conference presentation
Oct 23–Oct 27
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that first-time results from three pivotal clinical trials will be presented during late-breaking Presidential Symposia at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain from Oct. 23-27.Source filing
sacituzumab tirumotecan — Conference presentation
Oct 23–Oct 27
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that first-time results from three pivotal clinical trials will be presented during late-breaking Presidential Symposia at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain from Oct. 23-27.Source filing